Zsolt Papai-Szekely
Overview
Explore the profile of Zsolt Papai-Szekely including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
232
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kiss Z, Szabo T, Polgar C, Horvath Z, Nagy P, Fabian I, et al.
Front Oncol
. 2024 Oct;
14:1393132.
PMID: 39411131
Background: The nationwide HUN-CANCER EPI study examined cancer incidence and mortality rates in Hungary from 2011 to 2019. Methods: Using data from the National Health Insurance Fund (NHIF) and Hungarian...
2.
Galffy G, Szabo G, Tamasi L, Muller V, Moldvay J, Sarosi V, et al.
Pathol Oncol Res
. 2024 Jun;
30:1611754.
PMID: 38887697
Objective: Hungary has repeatedly been shown to have the highest cancer-related mortality and incidence in Europe. Despite lung cancer being the most abundant malignant diagnosis in Hungary, numerous concerns have...
3.
Papai-Szekely Z, Grmela G, Sarosi V
Pathol Oncol Res
. 2024 Jun;
30:1611774.
PMID: 38835723
Diagnostic bronchoscopy is a minimally invasive procedure that plays a crucial role in the diagnosis and management of various respiratory conditions. This paper explores the advancements in technology that have...
4.
Kerpel-Fronius A, Megyesfalvi Z, Markoczy Z, Solymosi D, Csanyi P, Tisza J, et al.
Eur Radiol
. 2023 Nov;
34(5):3462-3470.
PMID: 37921926
Objectives: The introduction of low-dose CT (LDCT) altered the landscape of lung cancer (LC) screening and contributed to the reduction of mortality rates worldwide. Here we report the final results...
5.
Heymach J, Harpole D, Mitsudomi T, Taube J, Galffy G, Hochmair M, et al.
N Engl J Med
. 2023 Oct;
389(18):1672-1684.
PMID: 37870974
Background: Neoadjuvant or adjuvant immunotherapy can improve outcomes in patients with resectable non-small-cell lung cancer (NSCLC). Perioperative regimens may combine benefits of both to improve long-term outcomes. Methods: We randomly...
6.
Kiss Z, Galffy G, Muller V, Moldvay J, Sarosi V, Papai-Szekely Z, et al.
Front Oncol
. 2023 Oct;
13:1207295.
PMID: 37860193
Objective: The approval of immunotherapy (I-O) for the treatment of late-stage non-small cell lung cancer (NSCLC) opened new perspectives in improving survival outcomes. However, survival data have not yet been...
7.
Robotka Z, Szabo K, Toth I, Szollosi Z, Barna T, Papai-Szekely Z, et al.
Orv Hetil
. 2023 Jul;
164(27):1077-1083.
PMID: 37422888
Mesenchymal tumors of the lungs are rare, mostly aggressive, with a high metastatic rate, representing only 0.013-1.1% of all pulmonary malignancies. Primary pulmonary myxoid sarcoma is an extremely rare type...
8.
Urban L, Doczi R, Vodicska B, Tihanyi D, Horvath M, Kormos D, et al.
Clin Lung Cancer
. 2020 Oct;
22(1):e112-e115.
PMID: 33082101
No abstract available.
9.
Markoczy Z, Sarosi V, Kudaba I, Galffy G, Turay U, Demirkazik A, et al.
BMC Cancer
. 2018 May;
18(1):598.
PMID: 29801465
Background: Erlotinib is approved for the first line treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer. Since the number of prospective studies in Caucasian patients treated...
10.
Dutau H, Breen D, Bugalho A, Dalar L, Daniels J, Dooms C, et al.
Respiration
. 2017 Sep;
95(1):44-54.
PMID: 28881352
Background: Airway stenting (AS) commenced in Europe circa 1987 with the first placement of a dedicated silicone airway stent. Subsequently, over the last 3 decades, AS was spread throughout Europe,...